Carayon P, Adler G, Roulier R, Lissitzky S
J Clin Endocrinol Metab. 1983 Jun;56(6):1202-8. doi: 10.1210/jcem-56-6-1202.
The TSH-displacing and the thyroid-stimulating activities of Graves' immunoglobulins G (GIgG) have been accounted for by either homogeneous TSH receptor antibodies or heterogeneous antibodies directed toward the TSH receptor-adenylate cyclase system. To clarify this matter, the study of the interactions of GIgG preparations from 14 untreated Graves' patients with human thyroid membranes was undertaken. Dose-response curves of GIgG, diluted in IgG from normal subjects, were carried out in the [125I]TSH radioreceptor assay and the adenylate cyclase assay in the presence or absence of TSH. In the radioreceptor assay, GIgG were constantly negative in 3 cases (21%) and positive, depending of the dose, in 11 cases. In the adenylate cyclase assay, the dose-activity profiles in the absence of TSH were bell-shaped curves in 3 cases and sigmoid curves in 9 cases; in 2 cases (14%), GIgG preparations were devoid of any effect. Binding-isotherms and dose-activity profiles did not appear to share simple relationships. In the presence of TSH, GIgG preparations elicited a decrease in 6 cases, an increase in 3 cases, and no effect in 5 cases (36%) in the adenylate cyclase activity. The data obtained by radioreceptor assay and adenylate cyclase assay in the presence or absence of TSH were found statistically correlated (P less than 0.05 to P less than 0.001) but not linearly related, the points being scattered on specific parts of the diagrams. These observations could not be accounted for by TSH receptor antibodies in GIgG being an entity of constant properties, albeit varying in titer among patients. Rather, GIgG effects fit well the patterns of action of a heterogeneous ligand, as shown by computing a theoretical model for ligand heterogeneity with respect to binding equilibrium constant and intrinsic biological activity. Accordingly, GIgG activity in the TSH receptor-adenylate cyclase system could be attributed to heterogeneous antibodies varying with regard to binding constant and acting as stimulating or blocking antibodies of the adenylate cyclase.
格雷夫斯病免疫球蛋白G(GIgG)的促甲状腺激素替代活性和甲状腺刺激活性,已被归因于针对促甲状腺激素受体的同质性抗体或针对促甲状腺激素受体-腺苷酸环化酶系统的异质性抗体。为阐明这一问题,对14例未经治疗的格雷夫斯病患者的GIgG制剂与人甲状腺膜的相互作用进行了研究。在[125I]促甲状腺激素放射受体测定和腺苷酸环化酶测定中,用来自正常受试者的免疫球蛋白G稀释GIgG,绘制剂量-反应曲线,测定有无促甲状腺激素时的情况。在放射受体测定中,3例(21%)GIgG始终呈阴性,11例根据剂量呈阳性。在腺苷酸环化酶测定中,无促甲状腺激素时的剂量-活性曲线在3例中呈钟形曲线,9例中呈S形曲线;2例(14%)GIgG制剂无任何作用。结合等温线和剂量-活性曲线似乎没有简单的关系。有促甲状腺激素存在时,GIgG制剂在6例中使腺苷酸环化酶活性降低,3例中升高,5例(36%)无作用。在有无促甲状腺激素时通过放射受体测定和腺苷酸环化酶测定获得的数据在统计学上相关(P小于0.05至P小于0.001),但不是线性相关,各点分散在图表的特定部分。这些观察结果不能用GIgG中的促甲状腺激素受体抗体是具有恒定特性的实体来解释,尽管患者之间的滴度有所不同。相反,GIgG的作用符合异质性配体作用模式,通过计算关于结合平衡常数和内在生物活性的配体异质性理论模型可以看出。因此,促甲状腺激素受体-腺苷酸环化酶系统中GIgG的活性可归因于结合常数不同、作为腺苷酸环化酶刺激抗体或阻断抗体起作用的异质性抗体。